RO7062931 ANTISENSE OLIGONUCLEOTIDE PHASE 1 STUDY DEMONSTRATES TARGET ENGAGEMENT IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) ON ESTABLISHED NUCLEOS(T)IDE THERAPY
| | | | | EASL virtual 2020 Aug 27-29
Reported by Jules Levin
Man-Fung Yuen1, Edward Gane2, Dong JoonKim3, Henry Lik-Yuen Chan4, Bernadette Surujbally5, VedranPavlovic5, Miriam Triyatni6, Joseph F. Grippo7, Tien Huey Lim8, Young-Suk Lim9, TawesakTanwandee10, Won Kim11, Wendy Cheng12, and Cynthia Wat51Queen Mary Hospital, Hong Kong, 2Auckland Clinical Studies, Auckland, New Zealand, 3Hallym University College of Medicine, Chuncheon, South Korea, 4Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, 5Roche Innovation Centre, WelwynGarden City, United Kingdom, 6Roche Innovation Centre, Basel, Switzerland, 7Roche Innovation Centre, New York, USA, 8Middlemore Hospital, Auckland, New Zealand, 9Asan Medical Center, Seoul, South Korea, 10Siriraj Hospital, Bangkok, Thailand, 11SMG-SNU BoramaeMedical Center, Seoul, South Korea, 12Linear Clinical Research, Perth, Australia
| | |
|  | |
|
|